ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas

NCT05079022 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
50
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Peking University People's Hospital

Collaborators